Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results

Quoin Pharmaceuticals Ltd. (QNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results – Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome; Primary and Key Secondary Endpoints Achieved Statistical Significance Versus

Event · Earnings
Original reporting
Published Nov 6, 2026, 10:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 10:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$QNRX
Bullish
high confidence
Mentioned
$QNRX
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$QNRXBullishHigh
01

Why it matters

The interim efficacy signals and new financing materially improve the company's near‑term outlook and could drive short‑term price appreciation.

02

Market read

The announcement provides fresh, material information for investors in QNRX and the broader rare‑disease biotech space.

03

What to watch

The upcoming recruitment completion and Q2‑2027 data readout remain uncertain, and the $50 M raise may dilute existing shareholders.

Relevance 8/10Novelty 9/10Timing: immediate
AlphAI · Earnings readQNRX · Q3 2026 · ended 2026-09-30

Quoin reports Q3 2026 net loss of $(4,870,759) as QRX003 Netherton Syndrome interim data reach statistical significance

→Mixed quarter

Clinical, regulatory and financing milestones were substantial in the quarter, while the company reports no revenue, its three-month and nine-month net losses both increased versus the prior-year periods, and cash of approximately $33.2 million is the stated funding base for ongoing development.

Key metrics

as reported
MetricValueq/qy/y
Total operating expenses, three months ended September 30, 2026GAAP$4,923,012––
General and administrative expenses, three months ended September 30, 2026GAAP$2,267,412––
Research and development expenses, three months ended September 30, 2026GAAP$2,655,600––
Unrealized (gain) loss, three months ended September 30, 2026GAAP$72,865––
Realized and accrued interest income, three months ended September 30, 2026GAAP$(125,118)––
Total other (income) and expenses, three months ended September 30, 2026GAAP$(52,253)––
Net loss, three months ended September 30, 2026GAAP$(4,870,759)––
Comprehensive loss, three months ended September 30, 2026GAAP$(4,868,043)––
Loss per ADS, basic, three months ended September 30, 2026GAAP$(0.97)––
Loss per ADS, fully-diluted, three months ended September 30, 2026GAAP$(0.97)––
Total operating expenses, nine months ended September 30, 2026GAAP$15,527,796––
General and administrative expenses, nine months ended September 30, 2026GAAP$5,811,266––
Research and development expenses, nine months ended September 30, 2026GAAP$9,716,530––
Unrealized (gain) loss, nine months ended September 30, 2026GAAP$84,580––
Realized and accrued interest income, nine months ended September 30, 2026GAAP$(372,840)––
Total other (income) and expenses, nine months ended September 30, 2026GAAP$(288,260)––
Net loss, nine months ended September 30, 2026GAAP$(15,239,536)––
Comprehensive loss, nine months ended September 30, 2026GAAP$(15,236,789)––
Loss per ADS, basic, nine months ended September 30, 2026GAAP$(4.26)––
Loss per ADS, fully-diluted, nine months ended September 30, 2026GAAP$(4.26)––
Cash, cash equivalents and marketable securities, as of September 30, 2026otherapproximately $33.2 million––

Capital returns

  • No share repurchases or dividends are reported in the filing.
  • Private placement announced August 28, 2026 with healthcare-focused institutional investors for up to approximately $50.0 million in gross proceeds, including initial upfront funding of approximately $30.8 million and up to an additional approximately $19.2 million upon the potential cash exercise of accompanying ordinary warrants.
  • The company states the August 2026 private placement provided funding to fully complete the development of QRX003 for Netherton Syndrome while enabling it to selectively invest in its pipeline.

What drove it

  • Interim results from Phase 2/3 study CL-QRX003-004 in Netherton Syndrome: four of six participants (66.7%) achieved the primary endpoint, a 1-grade or greater improvement in IGA, with p=0.0087 versus a pre-specified alpha of 0.0215. The key secondary endpoint achieved statistical significance at Week 12 (p=0.0070 versus a pre-specified alpha of 0.0215).
  • The company reports that all three participants with moderate to severe pruritus at baseline achieved a 3-grade or greater improvement in the Worst Itch NRS at Week 12, and that no treatment-related serious adverse events were reported.
  • FDA cleared the IND for QRX003 in Peeling Skin Syndrome on July 9, 2026. FDA granted Rare Pediatric Disease Designation on September 8, 2026 and Fast Track Designation on September 22, 2026 for QRX003 in PSS.
  • Subsequent to quarter end, the EMA granted Orphan Drug Designation to QRX003 for PSS on October 14, 2026. The company states QRX003 now holds eight regulatory designations from the FDA, the EMA and Japan's MHLW across Netherton Syndrome and PSS.
  • A peer-reviewed paper on QRX003 in Netherton Syndrome was published online October 13, 2026 in Dermatology and Therapy, including a pediatric case report under the Pediatric Compassionate Use Program in which the patient's IGA score improved from 4 (severe) at baseline to 0 (clear) by eight months.
  • The company states that the August 2026 private placement funds the completion of QRX003 development in Netherton Syndrome and selective investment in its pipeline.

Concerns

  • Net loss for the three months ended September 30, 2026 was $(4,870,759), compared with $(3,948,165) for the same quarter of 2025. Net loss for the nine months was $(15,239,536), compared with $(11,456,282).
  • Research and development expense for the nine months rose to $9,716,530 from $6,705,898, and G&A to $5,811,266 from $5,064,383. The filing does not state the reasons for these increases.
  • The Netherton Syndrome efficacy data are interim and based on the first six participants to complete 12 weeks of treatment. The study is ongoing, with topline data expected in the second quarter of 2027 per the company.
  • Up to $19.2 million of the private placement proceeds depends on the cash exercise of ordinary warrants and is not yet received. The release lists the initial upfront funding as approximately $30.8 million.
  • Ordinary shares outstanding increased from 52,441,360 at December 31, 2025 to 168,145,655 at September 30, 2026, and weighted average ADSs rose sharply year over year. Loss per ADS is therefore reported on a much smaller share base than in prior periods.
  • The company reports no revenue lines and no product approvals. Its stated timeline depends on completing recruitment of all 20 participants by year end and launching the PSS study before year end.

What to watch

  • Completion of recruitment of all 20 participants in CL-QRX003-004 by the end of 2026, as stated by the company.
  • Topline data from CL-QRX003-004 in the second quarter of 2027, as stated by the company.
  • Initiation of the planned Phase 2/3 study of QRX003 in Peeling Skin Syndrome, enrolling up to 12 pediatric and adult patients in the United States and Europe, before the end of 2026.
  • Receipt of the up to approximately $19.2 million from the cash exercise of ordinary warrants.
  • Submission of an IND to the FDA for an additional QRX009 indication before the end of 2026, and advancement of QRX009 toward clinical testing in early 2027.
  • Quarterly net loss trend and cash balance against the company's stated belief that current cash funds operations into 2028. The Form 10-Q is referenced as containing additional detail.

Balance sheet and cash flow

  • Cash and cash equivalents were $10,099,800 at September 30, 2026, compared with $3,818,096 at December 31, 2025. Investments were $23,083,738 compared with $14,927,165 at December 31, 2025. These year-end comparisons are not prior-year same-period figures and are shown here only as printed.
  • Total assets were $34,747,044 at September 30, 2026, compared with $20,390,569 at December 31, 2025.
  • Total liabilities were $6,049,261 at September 30, 2026, compared with $7,270,663 at December 31, 2025. Due to officers, long term, was $1,273,733 compared with $1,723,733. Accrued interest and financing expense was nil compared with $1,146,251.
  • Total shareholders' equity was $28,697,783 at September 30, 2026, compared with $13,119,906 at December 31, 2025.
  • Additional paid in capital was $114,905,632 compared with $84,090,966 at December 31, 2025. Accumulated deficit was $(86,209,983) compared with $(70,970,447).
  • Ordinary shares issued and outstanding were 168,145,655 (4,804,162 ADSs) at September 30, 2026, compared with 52,441,360 (1,498,325 ADSs) at December 31, 2025.
  • Weighted average ADSs outstanding, basic and fully-diluted, were 5,042,201 for the three months ended September 30, 2026, compared with 588,166 for the same period of 2025, and 3,576,795 for the nine months ended September 30, 2026, compared with 587,561 for the nine months ended September 30, 2025.
  • The company states its belief that its current cash position will fund operations into 2028. This is a forward-looking belief stated in the release, not a figure from the statements.
  • Operating cash flow and free cash flow are not printed in the filing.

Analysis

Quoin's third-quarter release is dominated by clinical and regulatory news rather than financial results. The company reports no revenue lines in the statement of operations. Its reported figures are operating expenses, other income and net loss. Total operating expenses for the quarter were $4,923,012, compared with $4,019,925 for the same quarter of 2025, with R&D at $2,655,600 (prior-year quarter $2,281,174) and G&A at $2,267,412 (prior-year quarter $1,738,751). Net loss for the quarter was $(4,870,759), against $(3,948,165) a year earlier. Nine-month figures show the same direction: net loss of $(15,239,536) versus $(11,456,282), and R&D of $9,716,530 versus $6,705,898.

The principal clinical item is the interim analysis of CL-QRX003-004 in Netherton Syndrome. Four of six participants (66.7%) achieved the primary endpoint, with p=0.0087 against a pre-specified alpha of 0.0215. The key secondary endpoint also reached significance at p=0.0070. The sample is small and the study is ongoing, with recruitment of 20 participants targeted by year end and topline data expected in the second quarter of 2027. The company describes the data as the first overall positive data set published for this disease. That is the company's characterization.

Regulatory activity expanded during the period. The FDA cleared the first IND for Peeling Skin Syndrome, and granted Rare Pediatric Disease and Fast Track Designations to QRX003 for PSS. The EMA granted Orphan Drug Designation after quarter end. The company states that QRX003 now holds eight regulatory designations across the FDA, EMA and Japan's MHLW. A planned PSS study is expected to start before year end.

On capital, the August private placement is the key financing event. The release describes up to $50.0 million in gross proceeds, with approximately $30.8 million upfront and up to approximately $19.2 million contingent on cash warrant exercise. Cash, cash equivalents and marketable securities were approximately $33.2 million at September 30, 2026. Shareholders' equity rose to $28,697,783 from $13,119,906 at December 31, 2025, and ordinary shares outstanding rose to 168,145,655 from 52,441,360. The company states its cash position is expected to fund operations into 2028. The filing does not print operating or free cash flow, so the cash burn rate cannot be read directly from the statements.

The filing contains no financial guidance. Its forward commitments are timing statements: recruitment completion, Netherton topline data in Q2 2027, PSS study initiation, and a QRX009 IND. Those milestones are the figures a reader should track against the quarterly loss and cash balance.

Management, verbatim

The third quarter substantially strengthened Quoin’s clinical, regulatory and financial foundation for long-term growth.

Dr. Michael Myers, Chief Executive Officer and Co-Founder

Our priorities for the coming months are very clear. We expect to complete recruitment in our Netherton Syndrome study by year end and report topline data in the second quarter of 2027.

Dr. Michael Myers, Chief Executive Officer and Co-Founder

Not in the filing

stated, not guessed
  • No revenue or sales lines are reported. Revenue, gross margin and cost of sales are not applicable to this filing.
  • No prior-quarter (Q2 2026) figures are printed, so qoq_change and prior_quarter fields are null.
  • Year-over-year percentage changes are not printed for any line item, so yoy_change fields are null.
  • No segment or geographic breakdown of revenue or expenses is printed.
  • No financial guidance (revenue, margin, operating expense or tax rate) is provided, so the guidance object is null.
  • Operating cash flow, investing cash flow, and free cash flow are not printed.
  • Income tax and interest expense lines are not printed separately.
  • Balance sheet comparisons are against December 31, 2025, not against the same period of the prior year, so they are presented in balance_sheet_cash_flow rather than as prior_year fields.
  • Cash, cash equivalents and marketable securities of approximately $33.2 million is given as text only; no line-item total is printed in the statements.
  • Net loss figures in the narrative are rounded (approximately $4.9 million and $3.9 million); statement figures are used in key_metrics.
  • No share repurchases, dividends or other capital return programs are reported.
  • The reasons for the increases in R&D and G&A expense are not stated in the filing.
  • The timing and amount of the up to $19.2 million warrant exercise proceeds are not printed as a date or schedule.
  • The previous outlook covered the second half of 2026 and items due by year end, not a figure for the third quarter that this release reports, so there is nothing to compare.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Quoin Pharmaceuticals (NASDAQ: QNRX) is a late‑stage specialty biotech focused on rare orphan diseases. The company reported its third‑quarter 2026 update.

Company-level read

Ticker impact

$QNRXBullishHigh confidence
Context

Quoin Pharmaceuticals disclosed positive interim Phase 2/3 data for QRX003 in Netherton Syndrome and announced a $50 million private placement, both first-time disclosures.

Expected impact

upward pressure as the market prices in the data and financing

Evidence & confidence

First report of statistically significant interim data and a sizable capital raise for a late‑stage biotech typically triggers buying interest.

Market effects

Strengthens the rare‑disease biotech sector and may lift peer companies with similar pipelines.

Adds positive sentiment to US biotech listings on NASDAQ.

Highlights progress in orphan‑drug development, relevant to global investors tracking rare‑disease therapeutics.

Counterpoint

If the interim data does not translate to a pivotal Phase 3 outcome, the hype could be premature.

Key entities

  • Quoin Pharmaceuticals Ltd.

    Late‑stage biotech developing QRX003 for Netherton and Peeling Skin Syndromes.

  • QRX003

    Investigational therapy showing positive interim Phase 2/3 data in Netherton Syndrome.

Every QNRX earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$QNRXHighAI 8/10

One girl’s skin regenerates 20 to 30 times faster than a peer’s. Her family shares what mornings are like.

Quoin Pharmaceuticals (QNRX) released a video featuring a mother and daughter living with Netherton Syndrome, a rare genetic skin disease. The episode highlights the daily challenges and medical care required. Quoin's investigational drug, QRX003, is in a Phase 2/3 trial, with topline data expected in Q2 2027. The company aims to raise awareness and develop treatments for the condition.

$QNRXMedAI 8/10

Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy

Quoin Pharmaceuticals Ltd. (QNRX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy – Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published – Case Report Details 21 Months of